Clinical Trials on Nutrition Assessment in Russian Federation

Total 723 results

Sanofi

Completed

GLP-1 Receptor Agonist Lixisenatide (Morning or Evening) in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin (GETGOAL-M)

Diabetes Mellitus, Type 2

United States, Canada, Romania, Russian Federation, Ukraine, Germany, Spain, Philippines, Czech Republic, Mexico, Croatia, Chile, Morocco, South Africa, Australia, Venezuela
Sanofi

Completed

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Sulfonylurea (GETGOAL-S)

Diabetes Mellitus, Type 2

United States, Romania, Russian Federation, Germany, Netherlands, Turkey, Bulgaria, India, Taiwan, Czech Republic, Tunisia, Japan, Egypt, Israel, Korea, Republic of, Thailand
Russian Federation of Anesthesiologists and Reanimatologists
Kuban State Medical University

Recruiting

The Role of Concomitant Diseases in Postoperative Complications Risk Stratification. (STOPRISK)

Stroke | Epilepsy | Diabetes | Chronic Kidney Diseases | Chronic Obstructive Pulmonary Disease | Neuromuscular Diseases | Parkinson's Disease | Anemia | Coronary Heart Disease | Chronic Heart Failure | Alzheimer's Disease | Bronchial Asthma | Heart Rhythm Disorders

Russian Federation
Akcea Therapeutics
Ionis Pharmaceuticals, Inc.

Terminated

The BROADEN Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Partial Lipodystrophy

Familial Partial Lipodystrophy

United States, Netherlands, Belgium, Brazil, Canada, Germany, Russian Federation
Hoffmann-La Roche

Completed

A Study of Adherence to Once Monthly Ibandronate (Bonviva) in Women With Post-Menopausal Osteoporosis, Supported by a Patient Relationship Program (PRP)

Postmenopausal Osteoporosis

Poland, Slovakia, Hungary, Russian Federation, Latvia, Romania, Slovenia
CSL Behring

Completed

Safety, Efficacy and Pharmacokinetics of ALD518 in Patients With Non-Small Cell Lung Cancer-related Fatigue and Cachexia

Fatigue | NSCLC | Cachexia

Canada, Australia, Russian Federation, Georgia, Serbia, India, New Zealand, Poland, Romania
Novo Nordisk A/S

Completed

STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity (STEP 1)

Overweight or Obesity | Metabolism and Nutrition Disorder

United States, India, Mexico, Russian Federation, United Kingdom, Canada, Denmark, Finland, Belgium, Japan, Taiwan, France, Poland, Germany, Bulgaria, Argentina, Puerto Rico
Relypsa, Inc.
Medpace, Inc.

Completed

Evaluation of Patiromer in Heart Failure Patients (PEARL-HF)

Heart Failure | Hyperkalemia

United States, Czechia, Georgia, Germany, Poland, Russian Federation, Ukraine
Alexion Pharmaceuticals

Completed

Retrospective, Non-interventional Natural History of Patients With Juvenile-onset Hypophosphatasia (HPP)

Hypophosphatasia (HPP)

United States, France, United Kingdom, Canada, Netherlands, Russian Federation, Turkey, Australia
Takeda

Completed

International Multicenter, Observational, Non-Interventional Prospective Study of Azilsartan Medoxomil in Participants With Arterial Hypertension Who Are Overweight or Obese in the Russian Federation and The Republic of Kazakhstan

Hypertension

Russian Federation, Kazakhstan
The Hospital for Sick Children

Active, not recruiting

International Rare Histiocytic Disorders Registry (IRHDR) (IRHDR)

Rare Histiocytic Disorders (RHDs) | Juvenile Xanthogranuloma (JXG) | Reticulohistiocytoma (Epithelioid Histiocytoma) | Xanthoma Disseminatum (XD) | Multicentric Reticulohistiocytosis (MRH) | Systemic Juvenile Xanthogranuloma | Erdheim-Chester Disease (ECD) | Multi-system Rosai-Dorfman Disease (RDD)

Canada, United States, Poland, Argentina, Austria, Czechia, Germany, Italy, Russian Federation, Spain
Vifor Pharma
Fresenius Medical Care North America

Completed

A Phase 3 Extension Study to Investigate the Long-term Safety, Tolerability and Efficacy of PA21, a Phosphate Binder in Dialysis Patients

Chronic Kidney Disease Requiring Chronic Dialysis

Latvia, United States, South Africa, Belgium, Croatia, Germany, Poland, Romania, Serbia, Ukraine, United Kingdom, Austria, Czech Republic, Lithuania, Russian Federation
OcuNexus Therapeutics, Inc.

Completed

A Study to Investigate the Safety and Clinical Effect of Nexagon® as a Topical Treatment for Subjects With a Diabetic Foot Ulcer (DUNE) (DUNE)

Diabetic Foot Ulcers

Russian Federation, United States, Ukraine
Sanofi

Completed

Lantus Versus Levemir Treat-To-Target (L2T3)

Diabetes Mellitus, Type 2

Korea, Republic of, Russian Federation, Spain, Denmark, Canada, Germany, Ireland, Portugal, Australia, India, Turkey, Netherlands, Sweden, United Kingdom, Finland, Switzerland, Romania, Brazil, Serbia, Taiwan
Eli Lilly and Company

Terminated

A Study of LY2599506 in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Russian Federation, Puerto Rico, Spain, United States, Australia
Sanofi
Regeneron Pharmaceuticals

Completed

An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (ODYSSEY KIDS)

Hypercholesterolaemia

Norway, Russian Federation, Sweden, South Africa, Czechia, United States, Canada, France, Netherlands, Spain
University of Ulm
University of Pisa; IRCCS Azienda Ospedaliero-Universitaria di Bologna; Medical... and other collaborators

Recruiting

Registry for Patients With Lipodystrophy (ECLip Registry)

Lipodystrophy Acquired | Lipodystrophy Congenital

Austria, France, Germany, Hungary, Italy, Portugal, Spain, Netherlands, Russian Federation, Slovenia, Switzerland, Turkey, United Kingdom
Eli Lilly and Company

Completed

A Study Comparing the Effects and Safety of Dulaglutide With Insulin Glargine in Type 2 Diabetes Mellitus (AWARD-CHN2)

Type 2 Diabetes Mellitus

China, Mexico, Korea, Republic of, Russian Federation
Sanofi

Completed

Assessment of the Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin +/- Metformin

Type 2 Diabetes Mellitus

China, India, Korea, Republic of, Russian Federation
Sanofi

Completed

GLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin (GETGOAL-X)

Diabetes Mellitus, Type 2

United States, Brazil, Poland, Russian Federation, Germany, Italy, Netherlands, Spain, Sweden, Argentina, Denmark, Finland, Hungary, Norway, Colombia, Austria, Greece, Puerto Rico
Eli Lilly and Company

Completed

Hyperglycemia and Cardiovascular Outcomes With Type 2 Diabetes (IONM)

Diabetes Mellitus, Type 2 | Acute Myocardial Infarction

Canada, Croatia, Czech Republic, Germany, Hungary, India, Israel, Lebanon, Poland, Romania, Russian Federation, Slovakia, Slovenia, South Africa, Spain, Turkey, United Kingdom
Novartis Pharmaceuticals

Completed

Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications (Navigator)

Diabetes Mellitus, Type 2

Austria, Argentina, Australia, Belgium, Brazil, Canada, Chile, China, Colombia, Denmark, Ecuador, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Italy, Malaysia, Mexico, Netherlands, Norway, Peru, Poland, Russian Federation and more
Rezolute

Completed

An Open-Label Multiple Dose Study of RZ358 in Patients With Congenital Hyperinsulinism

Congenital Hyperinsulinism

United States, Denmark, United Kingdom, Russian Federation, Spain, Bulgaria, Canada, Georgia, Germany, Israel, Turkey
Mannkind Corporation

Completed

Effects of URI on Diabetic Subjects Utilizing Technosphere Insulin After a Meal Challenge

Diabetes Mellitus | Upper Respiratory Infection

United States, Russian Federation, Canada
Novo Nordisk A/S

Terminated

Safety and Efficacy of Inhaled Pre-prandial Human Insulin in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

India, Macedonia, The Former Yugoslav Republic of, Russian Federation, Turkey, Croatia, Australia, Philippines
AstraZeneca

Completed

Faslodex in McCune-Albright Syndrome (FMAS)

Puberty, Precocious | McCune-Albright Syndrome

Italy, United States, Germany, France, Russian Federation, United Kingdom
Kuros Biosurgery AG

Completed

A Dose Finding Study of Topically Applied I-020201 as an Adjunct to Good Standard-of-care in Patients With Chronic Diabetic Foot Ulcers (DFU)

Diabetic Foot Ulcer

Czech Republic, Germany, Hungary, Romania, Russian Federation, Serbia
Novo Nordisk A/S

Completed

A Research Study, Looking at How Tresiba® Works in People With Type 2 Diabetes in Local Clinical Practice in Russia

Diabetes Mellitus, Type 2

Russian Federation
Sanofi

Completed

Efficacy and Safety of M100907 on Sleep Maintenance Insomnia With a Sub-study in Stable Type II Diabetes Mellitus (SAMS12)

Sleep Initiation and Maintenance Disorders

United States, France, Canada, Brazil, Russian Federation, Netherlands, Switzerland, Turkey, Malaysia, Taiwan, Czech Republic, Finland, Italy, Colombia, South Africa, Greece
Eli Lilly and Company

Completed

Comparison of Two Approaches to Insulin Therapy in Patients With Type 2 Diabetes (IOOX) (IOOX)

Diabetes Mellitus, Type 2

Australia, Russian Federation, Spain, Mexico, Canada, France, Korea, Republic of
Alexion Pharmaceuticals

Completed

Safety and Efficacy Study of Sebelipase Alfa in Participants With Lysosomal Acid Lipase Deficiency

Lysosomal Acid Lipase Deficiency

Spain, Germany, Italy, United States, Croatia, Canada, Russian Federation, Denmark, United Kingdom, Belgium, Mexico, Australia, Netherlands, Brazil, Turkey
Novo Nordisk A/S

Completed

Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis

Obesity

Spain, United States, France, Russian Federation, Canada, Colombia, South Africa, Norway, Denmark, Saudi Arabia, Sweden
Abbott

Completed

A 12-week Study to Compare the Efficacy and Safety of Fixed Combinations of Fenofibrate/Simvastatin 145/20mg and Fenofibrate/Simvastatin 145/40mg Tablets Versus Fenofibrate or Simvastatin Monotherapies in Subjects With Abnormal Blood Levels of Fats (Lipids) and at High Risk of Cardiovascular Disease

Dyslipidemia

Argentina, Czech Republic, Germany, Mexico, Poland, Romania, Russian Federation
Solvay Pharmaceuticals

Completed

Comparison of the Combination of Fenofibrate and Simvastatin Versus Pravastatin

Hyperlipidemia

Greece, Israel, Romania, Russian Federation, South Africa
Genzyme, a Sanofi Company

Completed

A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease (ENGAGE)

Gaucher Disease, Type 1

United States, United Kingdom, Bulgaria, Canada, Colombia, India, Israel, Lebanon, Mexico, Russian Federation, Serbia, Tunisia
AstraZeneca

Completed

A Study to Investigate the Safety and Efficacy of ZS in Patients With Hyperkalemia (HARMONIZE GL)

Hyperkalemia

Korea, Republic of, Taiwan, Russian Federation, Japan
Novo Nordisk A/S

Completed

Safety Follow-up on Children and Adolescents With Type 1 Diabetes Treated With Insulin Detemir. An Extension to Trial NN304-1689

Diabetes | Diabetes Mellitus, Type 1

France, Denmark, Finland, Russian Federation, Macedonia, The Former Yugoslav Republic of, Hungary, Bulgaria, United Kingdom, Turkey, Czech Republic, Poland
Eli Lilly and Company

Active, not recruiting

A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight (SURMOUNT-1)

Obesity | Overweight

United States, Taiwan, India, China, Japan, Mexico, Brazil, Puerto Rico, Argentina, Russian Federation
Eli Lilly and Company

Completed

A Study for Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Russian Federation, Puerto Rico, United States, Australia, Hungary, Poland, Romania, Spain
Alexion Pharmaceuticals

Completed

Open-Label Study of Asfotase Alfa in Infants and Children ≤ 5 Years of Age With Hypophosphatasia (HPP)

Hypophosphatasia

United States, Spain, Australia, United Kingdom, Italy, France, Canada, Germany, Japan, Russian Federation, Saudi Arabia, Turkey
Novo Nordisk A/S

Completed

Diabetes Attitudes Wishes and Needs (DAWN2)

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1 | Relatives to/Carers of Patients | Healthcare Professionals

Spain, Algeria, China, India, Mexico, Russian Federation, Turkey, Germany, Poland, Japan, Netherlands, Italy, Canada, United Kingdom, Denmark, France, United States
AstraZeneca

Completed

Epanova® for Lowering Very High Triglycerides II (EVOLVE II) (EVOLVEII)

Hypertriglyceridemia

Denmark, United States, Hungary, Netherlands, Russian Federation, Czechia, Canada
Novo Nordisk A/S

Completed

Observational Study on the Effect of NovoMix® 30, Levemir® or NovoRapid® (Alone or Combined) in Type 2 Diabetics Previously Treated With Anti-diabetic Medication (A1chieve®)

Diabetes Mellitus, Type 2 | Diabetes

Saudi Arabia, Algeria, Argentina, Bangladesh, China, Egypt, India, Indonesia, Iran, Islamic Republic of, Jordan, Korea, Republic of, Libyan Arab Jamahiriya, Malaysia, Mexico, Morocco, Pakistan, Philippines, Russian Federation and more
Sanofi

Completed

Efficacy and Safety Comparison of Metformin/Glimepiride Combination Versus Each Compound Alone in New Diagnosed Type 2 Diabetes Patients (RECOMMEND)

Diabetes Mellitus, Type 2

Algeria, Colombia, Egypt, Guatemala, India, Iran, Islamic Republic of, Lebanon, Mexico, Russian Federation, South Africa, Tunisia, Turkey, Ukraine, United Arab Emirates
GlaxoSmithKline

Completed

A Fixed Dose, Dose Response Study for Ropinirole Prolonged Release in Patients With Early Stage Parkinson's Disease (TANDEM-662)

Parkinson Disease

United States, Estonia, Korea, Republic of, Russian Federation, Slovakia
Novo Nordisk A/S

Completed

Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity (STEP 2)

Obesity | Overweight

United States, India, Japan, Russian Federation, United Kingdom, Canada, Spain, South Africa, Germany, Greece, United Arab Emirates, Argentina, Puerto Rico
Eli Lilly and Company

Completed

Comparison of Two Basal Insulin Therapies for Patients With Type 1 Diabetes (IOOZ)

Diabetes Mellitus, Type 1

Russian Federation, United States, Australia, Greece, Argentina, Hungary, Brazil, Mexico, Romania
Novartis Pharmaceuticals

Completed

A Pilot Study to Assess the Efficacy and Safety of LCQ908 Alone and in Combination With Fenofibrate or Lovaza® in Patients With Severe Hypertriglyceridemia

Non Familial Chylocmicronemia Syndrome (Non-FCS)

United States, Canada, Russian Federation
GlaxoSmithKline

Completed

A Comparison of Atorvastatin and Glimepiride Fixed Dose Combination and Atorvastatin and Glimepiride Loose Combination in the Treatment of Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Korea, Republic of, Malaysia, Philippines, Thailand, Russian Federation, Mexico
Boehringer Ingelheim

Completed

This International Study Tests BI 690517 in Patients With Diabetic Kidney Disease. The Study Tests How 3 Different Doses of BI 690517 Are Taken up in the Body and How Well They Are Tolerated

Diabetic Nephropathies

Spain, Germany, United Kingdom, France, Greece, Portugal, Sweden, Russian Federation, Denmark, Slovakia

Clinical Trials on Nutrition Assessment in Russian Federation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations